Search Results - "Bowles, D W"

XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer by Morton, J J, Bird, G, Keysar, S B, Astling, D P, Lyons, T R, Anderson, R T, Glogowska, M J, Estes, P, Eagles, J R, Le, P N, Gan, G, McGettigan, B, Fernandez, P, Padilla-Just, N, Varella-Garcia, M, Song, J I, Bowles, D W, Schedin, P, Tan, A-C, Roop, D R, Wang, X-J, Refaeli, Y, Jimeno, A

“…The limitations of cancer cell lines have led to the development of direct patient-derived xenograft models. However, the interplay between the implanted human…”
Get full text

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours by Bowles, D W, Ma, W W, Senzer, N, Brahmer, J R, Adjei, A A, Davies, M, Lazar, A J, Vo, A, Peterson, S, Walker, L, Hausman, D, Rudin, C M, Jimeno, A

“…Background: This phase I, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), pharmacokinetics, and…”
Get full text

Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time‐dependent Changes in the Absence of Clinical Nephrotoxicity by George, B, Wen, X, Mercke, N, Gomez, M, O'Bryant, C, Bowles, DW, Hu, Y, Hogan, SL, Joy, MS, Aleksunes, LM

“…The success of cisplatin‐containing regimens to treat solid tumors is limited, in part, by nephrotoxicity. In rodents, several urinary proteins have emerged…”
Get full text

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study by Kurzrock, R., Bowles, D.W., Kang, H., Meric-Bernstam, F., Hainsworth, J., Spigel, D.R., Bose, R., Burris, H., Sweeney, C.J., Beattie, M.S., Blotner, S., Schulze, K., Cuchelkar, V., Swanton, C.

“…Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor…”
Get full text

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial by Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C.S., Tan, D.S.W., Lee, D.H., Misch, D., Garralda, E., Kim, D.-W., van der Wekken, A.J., Gainor, J.F., Paz-Ares, L., Liu, S.V., Kalemkerian, G.P., Houvras, Y., Bowles, D.W., Mansfield, A.S., Lin, J.J., Smoljanovic, V., Rahman, A., Kong, S., Zalutskaya, A., Louie-Gao, M., Boral, A.L., Mazières, J.

“…RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET…”
Get full text

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies by Ross, J.S., Gay, L.M., Wang, K., Vergilio, J.A., Suh, J., Ramkissoon, S., Somerset, H., Johnson, J.M., Russell, J., Ali, S., Schrock, A.B., Fabrizio, D., Frampton, G., Miller, V., Stephens, P.J., Elvin, J.A., Bowles, D.W.

“…Relapsed/metastatic salivary gland carcinomas (SGCs) have a wide diversity of histologic subtypes associated with variable clinical aggressiveness and response…”
Get full text

Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations by Wang, K, McDermott, J D, Schrock, A B, Elvin, J A, Gay, L, Karam, S D, Raben, D, Somerset, H, Ali, S M, Ross, J S, Bowles, D W

“…We sought to identify genomic alterations (GAs) in salivary mucoepidermoid carcinomas. DNA was extracted from 48 mucoepidermoid carcinomas. Comprehensive…”
Get full text

Targeted therapies for ROS1-rearranged non-small cell lung cancer by Patil, T, Simons, E, Mushtaq, R, Pacheco, J M, Doebele, R C, Bowles, D W

Get full text

Characterization of Rb uptake into Sf9 cells using cation chromatography: evidence for a K–Cl cotransporter by Bowles, Daniel W, M. Gillen, Christopher

“…To assess cation–chloride cotransporter activity in Sf9 cells, cation chromatography was used to measure initial uptake rates of Rb. Rb exchanged with cellular…”
Get full text

New therapies for anaplastic thyroid cancer by Agrawal, V R, Hreno, J, Patil, T, Bowles, D W

“…Anaplastic thyroid cancer is a rare but extremely aggressive type of thyroid cancer. Treatment typically consists of surgery, external beam radiotherapy and…”
Get full text

Update on multikinase inhibitor therapy for differentiated thyroid cancer by Agrawal, V R, Jodon, G, Mushtaq, R, Bowles, D W

“…Curative therapies for radioiodine-refractory differentiated thyroid cancer remain lacking. However, oral multikinase inhibitors often allow for disease…”
Get full text

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium by Khaki, A.R., Wise-Draper, T.M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Painter, C.A., Peters, S., Rini, B.I., Mishra, S., Rivera, D.R., Acoba, J.D., Bashir, B., Bekaii-Saab, T., Berg, S., Bernicker, E.H., Bilen, M.A., Bindal, P., Bishnoi, R., Bouganim, N., Bowles, D.W., Cabal, A., Caimi, P.F., Crowell, J., Desai, A., Dixon, B., Doroshow, D.B., Durbin, E.B., Farmakiotis, D., Fazio, A., Fecher, L.A., Friese, C.R., Fu, J., Gadgeel, S.M., Glover, M.J., Goyal, S., Grover, P., Gulati, S., Gupta, S., Halabi, S., Halfdanarson, T.R., Halmos, B., Hausrath, D.J., Hawley, J.E., Hsu, E., Jani, C., Jayaraj, A., Johnson, D.B., Kasi, A., Khan, H., Kuderer, N.M., Kwon, D.H., Li, A., Loaiza-Bonilla, A., Low, C.A., Lustberg, M.B., Lyman, G.H., McKay, R.R., McNair, C., Menon, H., Mesa, R.A., Mundt, D., Nagaraj, G., Nakasone, E.S., Nizam, A., Nock, N.L., Patel, J.M., Patel, K.G., Peddi, P., Pennell, N.A., Piper-Vallillo, A.J., Puc, M., Reeves, M.E., Reuben, D.Y., Rosovsky, R.P., Salazar, M., Schmidt, A.L., Schwartz, G.K., Shah, M.R., Shah, S.A., Shah, C., Shaya, J.A., Stockerl-Goldstein, K.E., Streckfuss, M., Subbiah, S., Tachiki, L., Thakkar, A., Tucker, M.D., Verma, A.K., Vinh, D.C., Weiss, M., Wu, J.T., Wulff-Burchfield, E., Xie, Z., Yu, P.P., Zhou, A.Y., Zhu, H., Zubiri, L., Warner, J.L., Lopes, GdL

“…Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort…”
Get full text

Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer by Bowles, D W, Weickhardt, A, Jimeno, A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are valuable treatments for EGFR-mutated non-small cell lung cancer (NSCLC)…”
Get full text

Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib) by Bowles, D W, Kessler, E R, Jimeno, A

“…XL-184 (cabozantinib) is a novel, small-molecule, multitargeted receptor tyrosine kinase inhibitor with particular activity against hepatocyte growth factor…”
Get full text

Cabozantinib use in renal cell carcinoma by Neuwelt, A J, Mathur, S, Johnson, A T, Kessler, E R, Bowles, D W

“…In the last several years, many new drugs have been approved to treat metastatic renal cell carcinoma (RCC). Cabozantinib is a novel multikinase inhibitor with…”
Get full text

New and established tyrosine kinase inhibitors for chronic myeloid leukemia by Thienelt, C D, Green, K, Bowles, D W

“…Chronic myeloid leukemia (CML) is an uncommon malignancy, the treatment and prognosis of which have dramatically shifted over the last decade. Characterized by…”
Get full text

Tivozanib: practical implications for renal cell carcinoma and other solid tumors by Berge, E M, Bowles, D W, Flaig, T W, Lam, E T, Jimeno, A

“…Tivozanib is a recently developed, small-molecule tyrosine kinase inhibitor with specific affinity for the vascular endothelial growth factor receptor (VEGFR)…”
Get full text

Axitinib, a new therapeutic option in renal cell carcinoma by Kessler, E R, Bowles, D W, Flaig, T W, Lam, E T, Jimeno, A

“…Axitinib is a small-molecule protein-tyrosine kinase receptor inhibitor specifically targeting this family of receptors, in addition to platelet-derived growth…”
Get full text

Results of a Multi-Institutional Phase II Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiotherapy by Vinogradskiy, Y., Castillo, R., Castillo, E., Schubert, L.K., Jones, B.L., Faught, A.M., Gaspar, L.E., Kwak, J., Bowles, D.W., Waxweiler, T.V., Dougherty, M., Gao, D., Stevens, C.W., Miften, M., Kavanagh, B.D., Grills, I.S., Rusthoven, C.G., Guerrero, T.M.

“…Pulmonary toxicity, and in particular radiation pneumonitis, remains a major limitation in the radiotherapy treatment of lung cancer patients. Functional…”
Get full text

Vismodegib in basal cell carcinoma by Amaria, R N, Bowles, D W, Lewis, K D, Jimeno, A

“…Vismodegib is a novel, small-molecule inhibitor of smoothened, a key component of the hedgehog signaling pathway. Increased hedgehog pathway signaling is…”
Get full text